Cal Bontemps Appointed Radians Director of Marketing

Cal Bontemps

Radians®, a top-tier global PPE manufacturer, is excited to announce the appointment of Cal Bontemps as its new Director of Marketing.

Experience

With an impressive career spanning over 24 years in sales, product management, customer engagement, and digital marketing communications, Bontemps brings a wealth of expertise to lead the marketing team while driving strategic alignment with Radians’ sales goals and objectives.

During his 18-year tenure at Medtronic, a global producer of medical devices and therapies, Cal Bontemps showcased exceptional vision and orchestrated numerous omni-channel marketing campaigns, generating multi-million-dollar sales by introducing groundbreaking new therapies into the medical industry.

New Role

In his new role at Radians, Bontemps will oversee and execute the company’s comprehensive marketing and customer engagement strategy. His primary focus will be to enhance brand visibility and deliver cutting-edge solutions that cater to the unique needs of distributors and stakeholders.

Radians President Bill England

“We are excited to welcome Cal to the team. His leadership in strategic marketing, market analysis, team building, and digital strategies will play a pivotal role as we continue to grow and scale as an organization.”

Bontemps is thrilled to assume the leadership role of the Radians marketing team, bringing a wealth of expertise and enthusiasm that will propel the company to even greater heights in the future. “Medical devices and PPE share the common goal of bringing health and safety to others, so, I feel right at home here.  I look forward to shaping the company’s strategy in the coming years, leveraging data-driven approaches to create compelling success stories for both Radians and the customers we serve,” said Bontemps.

SourceRadians®

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”